INDIA NON JUDICIAL

Government of Uttar Pradesh

IN-UP24610131088133X

e-Stamp

ACC Name GEETA
Stamp Vender
Licence No..17/97-98
Stamping ACC ID:UP1444670

Certificate No.	:	IN-UP24610131088133X
Certificate Issued Date	:	29-Dec-2025 07:49 PM
Account Reference	:	NEWIMPACC (SV)/ up14446704/ MATHURA SADAR/UP-MTH
Unique Doc. Reference	:	SUBIN-UPUP144467044566144739273OX
Purchased by	:	GLA UNIVERSITY MATHURA
Description of Document	:	Article 34 Indemnity Bond
Property Description	:	Not Applicable
Consideration Price (Rs.)	:	
First Party	:	GLA UNIVERSITY MATHURA
Second Party	:	Not Applicable
Stamp Duty Paid By	:	GLA UNIVERSITY MATHURA
Stamp Duty Amount(Rs.)	:	100 (One Hundred only)

Please write or type below this line

MEMORANDUM OF UNDERSTANDING
BETWEEN
GLA University, Mathura, Uttar Pradesh, India
AND
SIGNA Pharma Private Limited, Kanpur, Uttar Pradesh, India

This Memorandum of Understanding (MoU) is being signed on the ...01 January 2026 between The GLA University, established under U.P. State Legislative Act of 2009 (UP Act 21 of 2010) and ranked among the top Universities of Uttar Pradesh and India and has been accredited by the National Assessment and Accreditation Council **(NAAC) with 'A⁺⁺' Grade** and recognized by University Grants Commission (UGC) under section 12B of UGC Act of 1956, having its campus at NH-2, Mathura-Delhi Road P.O. Chaumuhan, Mathura, Uttar Pradesh, India 281406. (Hereinafter referred to as "GLAU)". Pharmacy department of GLAU has received **NIRF Ranking 48** in the year 2025.

And

Signa Pharma Private Limited, an unlisted private company, having corporate identification number - U24231UP1984PTC006453 and its registered office at 123/452 Factory Area Fazalganj, Kanpur, Uttar Pradesh – 208012 (hereinafter referred to as "Signa"). Customer centricity is at the core of Signa, and it is this belief that has led the business to build long-term relationships. Ensuring a positive customer experience, making available goods and/or services that are of top-notch quality is given prime

For Signa Pharma Pvt. Ltd.

Managing Director

Ashok Kumar Singh
Registrar
GLA University, Mathura

Statutory Alert:
1. The authenticity of this Stamp certificate should be verified at 'www.shcilestamp.com' or using e-Stamp Mobile App of Stock Holding. Any discrepancy in the details on this Certificate and as available on the website / Mobile App renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

GLA UNIVERSITY MATHURA GLA UNIVERSITY MATHURA GLA UNIVERSITY MATHURA GLA UNIVERSITY MATHURA GLA UNIVERSITY MATHURA GLA UNIVERSITY MATHURA GLA UNIVERSITY MATHURA

importance by Signa. This business has a wide range of product offerings, and the product/catalogue list includes hard gelatin capsule and Syrup.

Both the Parties agree to work in the area of research and undertake that specific areas under the MoU may be proposed, formulated and agreed upon by them for the implementation of this MoU and for the said areas. GLA University and/or SIGNA Pharma Private Limited, assigned shall consider the same as part of this MoU.
The two institutions will endeavor to cooperate as follows:

1. OBJECTIVES

This MoU aims to build a long term relationship and to develop healthy and stable arrangements between both the Parties. Any collaborative programs, projects or activities proposed under the auspices of this MoU shall be subject to negotiation, agreement and approval by, and between, the Parties. The forms of these collaborative programs, projects or activities may include but are not limited to:

1. Summer industrial training to the bachelor of pharmacy students.
2. Educational tours to the diploma, bachelor and master of pharmacy students.
3. Provide sample of drugs for research/academic purpose.
4. Utilization of lab facility of Institute of Pharmaceutical Research by Signa Pharma.
5. Campus placement of GLAU students.
6. Guest Lectures for students from Industry Experts

The parties will work out a specific plan for any activity mentioned above; and mutually discuss the detailed arrangement for collaboration. The terms and conditions for such activities as deliverables, funding, developers, intellectual property will have to be specified in a separate work specific agreement.

2. ROLES & RESPONSIBILITIES OF EACH PARTY

1. Research lab and resources will be provided by GLA University, Mathura.
2. Guest Lectures for students from Industry Experts.
3. Campus placement drive.
4. Industry visit.
5. Summer training programs for B Pharm students.
6. Gift samples of drugs for academic/research purpose.

3. FINANCIAL ARRANGEMENT

The financial arrangement for the co-operative activities undertaken within the framework of this MoU shall be mutually agreed upon by both the Parties on a case-to-case basis, subject to the availability of funds and resources.

4. REPRESENTATION AND WARRANTY

Each Party to this MoU represents that the execution and performance of this MoU is not contrary to any rule, law, statute, internal policy, or any other such order or rule by which such Party is bound.

5. PROTECTION OF INTELLECTUAL PROPERTY RIGHTS/ OWNERSHIP

Each party will protect, its territory, intellectual property rights of the other party in force in their respective countries. All copyrights, design rights, rights relating to computer software or intellectual

For Signa Pharma Pvt. Ltd.

Managing Director

Ashok Kumar Singh
Registrar
GLA University, Mathura

property rights of the documents produced in support of any activity under this MoU shall remain with the Party owning it.

Ownership of any intellectual property (including but not limited to confidential information, know-how, patents, copyrights, design rights, rights relating to computer software, and any other industrial or intellectual property rights) developed during the course of this MoU shall be decided through a separate project specific agreement.

6. CONFIDENTIALITY

a. Confidential information includes all communication of information disclosed in documentary or tangible form between the Parties, including oral, written and machine-readable form, pertaining to the above which is indicated as confidential. In the case of such information disclosed orally or visually, the Disclosing Party shall confirm in writing the fact and general nature of each disclosure within (30) days after it is made.

b. Confidential information includes information:
   1. Disclosed by, or on behalf of, the Disclosing Party to the Receiving Party,
   2. Otherwise learned or ascertained by the Receiving party from inspection and/or evaluation of sample(s) identified by the Disclosing party as confidential and provided to the Receiving party by or on behalf of the Disclosing Party (sample(s)) and/or,
   3. Otherwise learned or ascertained by the Receiving Party from the Disclosing Party.

c. The Receiving Party will not disclose confidential information of the Disclosing Party to any other person and use at least the same degree of care to maintain the Information confidential as receiving party uses in maintaining as confidential its own confidential Information, but always at least a reasonable degree of care; due diligence will be taken by both the parties in maintenance of confidential information.

d. The Receiving Party will use the confidential information only for the above mentioned purpose.

e. The Receiving Party will restrict disclosure of the confidential information of the Disclosing Party solely to those employees, subsidiaries, parent and affiliated companies of Receiving Party having a need to know such Information in order to accomplish the purpose stated above.

f. This MoU imposes no obligation on Receiving Party with respect to any portion of the confidential information received from Disclosing Party which:
   i. Was known to Receiving Party prior to disclosure by Disclosing Party,
   ii. Is lawfully obtained by Receiving Party from a third party under no obligation of confidentiality,
   iii. Is, or becomes, generally known or publicly available other than by unauthorized disclosure, is independently developed by Receiving Party,
   iv. Is disclosed by disclosing Party to a third party without a duty of confidentiality on the third party.
   v. Is required by law or decree.

g. The confidential information shall remain the sole property of the Disclosing Party.

For Signa Pharma Pvt. Ltd.

Managing Director

Ashok Kumar Singh
Registrar
GLA University, Mathura

h. The obligation of non-disclosure of confidential information shall survive for 10 years after expiry/termination of this MoU.

7. SUSPENSION

Each party reserves the rights for reasons of national security, national interest, public order or public health to suspend temporarily either in whole or in part the implementation of this MoU. The suspension shall take effect immediately after written notification has been given to the other party through diplomatic channels.

8. REVISION, MODIFICATION AND AMENDMENT

Either Party may request in writing a revision, modification or amendment of all or any part of this MoU. Any revision, modification or amendment agreed to by the parties shall be reflected in writing and shall form part of this MoU. Such revision, modification or amendment shall come into force on such date as may be determined by parties.

9. SETTLEMENT OF DISPUTES

The MoU is not intended to create any legal obligations between the Parties. Any difference or dispute between the Parties concerning the interpretation and/ or implementation and / or applicable to any of the provisions of this MoU shall be settled amicably through mutual consultation and / or negotiation between the Parties, without reference to any third party or international tribunal.

Both parties also acknowledge the existence of certain legal constraints and policy directives of the government of India.

In case any disputes arise in implementing the MoU, these shall be resolved by mutual consultation.

10. EFFECTIVE DATE, DURATION AND TERMINATION

The MoU shall commence from the Effective Date and shall continue for a period of Ten (10) years from the Effective Date (hereafter referred to as "Term"). Thereafter, both parties shall review the status of this co-operation and may extend the Term on such conditions as mutually agreed upon.

Notwithstanding the10 paragraph 1 above, either party may terminate this MoU by notifying the other Party in writing at least Six (6) months in advance of such termination.

10.1 Unless otherwise agreed upon by the Parties, the termination of this MoU shall not affect the implementation of the on-going activities and/or programs, which have been agreed upon before the date of the termination of the MoU.

11. SINGLE POINT OF CONTACT (SPOC)

Each party shall designate a person or office to serve as liaison for implementing this MoU. The liaison/ SPOC may change from time to time upon notice given to the other party in writing pursuant to this MoU.

For the SIGNA Pharma Private Limited:

Name- Dr Saurabh Bhargava
Designation- Managing Director
Email ID- signapharma@gmail.com
Contact Number- 9696543210

For Signa Pharma Pvt. Ltd.

Managing Director

Ashok Kumar Singh
Registrar
GLA University, Mathura

For the GLA University:
Name: Dr. Yogesh Murti
Designation: Associate Professor, Institute of Pharmaceutical Research, GLAU
Email ID: yogesh.murti@gla.ac.in
Contact Number: +91 8006240340.

12. INDEMNIFICATION

Both the parties shall indemnify and keep the other party indemnified and harmless against any and all claims, actions, proceedings by third party (including all costs, expenses, damages/ losses) arising out of or in connection with this MoU due to breach of any provisions of this agreement Memorandum of Understanding by such party or as a result of any act of negligence/omission or commission on part of such party and /or its employees, agents etc.

13. FORCE MAJEURE

13.1 Neither party hereto shall be liable for any failure to perform its obligations hereunder to the extent that performance has been delayed, hindered or prevented by any circumstances beyond the reasonable control of that party, including without prejudice to the generality of the foregoing, any act of God, war, riot, civil commotion, strike, lock-out or other form of industrial action or any form of government or supernatural authority intervention.

13.2 The affected party to be able to avail of this clause will be obliged to inform the other party of:

(a) The occurrence of any such event of force majeure; and
(b) Resume its responsibilities on the cessation of such force majeure event.

14. MISCELLANEOUS

14.1 Neither party shall use or publicize the MoU in such a manner as to cause any disrepute to the other party and shall not make any statement relevant to this MoU which may reasonably be considered to be misleading.

14.2 If any doubt arises as to the interpretation of the provisions of this Agreement or as to matters not provided therein, the parties to this Agreement shall consult with each other for each instance and resolve such doubts in good faith.
14.3 In case of dispute or difference arising out of, or in connection with, this MoU; the same shall be settled through mutual discussions between GLA University, Mathura and SIGNA Pharma Private Limited, Kanpur.

For Signa Pharma Pvt. Ltd.

Managing Director

Ashok Kumar Singh
Registrar
GLA University, Mathura

IN WITNESS WHEREOF the parties hereto have signed & executed this memorandum in presence of each other and in presence of attesting witnesses.

For and on behalf of
GLA University, Mathura, India

Mr. Ashok Kumar Singh
Registrar

Ashok Kumar Singh
Registrar
GLA University, Mathura

Witness 1:

Prof. Kamal Shah
HOD
Institute of Pharmaceutical Research
GLA University, Mathura

Date: - 01/01/2026

For and on behalf of
SIGNA Pharma Private Limited, Kanpur

Dr Saurabh Bhargava
Managing Director

For Signa Pharma Pvt. Ltd.
Managing Director

Witness 1:

Mrs. Rinku Bhargava,
Director
SIGNA Pharma Pvt Ltd, Kanpur

Date:- 01/01/2026